Soluble Intercellular Adhesion Molecule-1 Concentrations in Patients with Subacute Thyroiditis and in Patients with Graves' Disease with or without Ophthalmopathy

Increased circulating soluble ICAM-1 (sICAM-1) levels has been previously reported in Graves' disease (GD) patients with or without ophthalmopathy (GO) and in patients with toxic nodular goiter but not in patients with subacute thyroiditis. Conflicting results have also been reported about the...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine Journal 1996, Vol.43(5), pp.517-525
Main Authors: OZATA, METIN, BOLU, EROL, SENGÜL, ALI, ALTINSOY, H. IBRAHIM, TURAN, MUSTAFA, CORAKCI, AHMET, HACIBEKTASOGLU, AZIZ, GUNDOGAN, M. ALI
Format: Article
Language:English
Subjects:
Adult
Autoantibodies - blood
Autoantibodies - immunology
Biomarkers - blood
Cohort Studies
Enzyme-Linked Immunosorbent Assay
Female
Glucocorticoids - pharmacology
Graves Disease - blood
Graves Disease - classification
Graves Disease - drug therapy
Graves' disease
Humans
Intercellular Adhesion Molecule-1 - blood
Intercellular Adhesion Molecule-1 - chemistry
Intercellular Adhesion Molecule-1 - drug effects
Intercellular Adhesion Molecule-1 - immunology
Male
Ophthalmopathy
sICAM-1
Solubility
Subacute thyroiditis
Thyroiditis, Subacute - blood
Thyroiditis, Subacute - drug therapy
Thyrotropin - blood
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Increased circulating soluble ICAM-1 (sICAM-1) levels has been previously reported in Graves' disease (GD) patients with or without ophthalmopathy (GO) and in patients with toxic nodular goiter but not in patients with subacute thyroiditis. Conflicting results have also been reported about the usefulness of sICAM-1 levels as a marker for the activity of hyperthyroidism. We have therefore determined sICAM-1 levels by a sandwich enzyme linked immunosorbent assay (ELISA) method in 10 patients with subacute thyroiditis (Group 1), who are at the initial or acute phase of thyroiditis, in 10 hypothyroidic patients with Hashimoto's thyroiditis (Group 2), in 10 patients with euthyroid nodular goiter (Group 3), in 10 patients with untreated GD patients with active ophthalmopathy (Group 4), in 10 hyperthyroid GD patients without clinical ophthalmopathy (Group 5), in 10 patients with GO who are euthyroid and treated with glucocorticoids for 3 months (Group 6) and in 20 normal subjects (Control Group). Groups 1, 2, 4, 5 and 6 (P
ISSN:0918-8959
1348-4540
DOI:10.1507/endocrj.43.517